Regis Coutant, Elise Bismuth, Elisabeth Gilbert-Bonnemaison, Fabienne Dalla-Vale, Paul Morinais, Maelys Perrard, Jeanne Trely, Nathalie Faure, Natacha Bouhours-Nouet, Lucie Levaillant, Anne Farret, Caroline Storey, Aurelie Donzeau, Amelie Poidvin, Jessica Amsellem-Jager, Jerome Place, Emmanuel Quemener, Jean-François Hamel, Marc D Breton, Nadia Tubiana, Eric Renard
Background It is unclear whether hybrid closed-loop therapy (HCL) attenuates the metabolic impact of missed or suboptimal meal insulin bolus compared with sensor-augmented pump therapy (SAP) in children with type 1 diabetes in free-living conditions. Methods This is an ancillary study from a multicenter randomized controlled trial that compared 24/7 HCL to evening and night (E/N) HCL for 36 weeks in children between 6 and 12 years old. In the present study, the 60 children from the E/N arm underwent a SAP phase, an evening and night (E/N) HCL for 18 weeks, then a 24/7 phase for 18 weeks, extended for 36 more weeks...
March 16, 2023: Diabetes Technology & Therapeutics